Phase 1CompletedAge-related condition
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
A Phase I Clinical Trial for BAT5906(Single-dose;for Injection) on Safety and Pharmacokinetics for Patients With Age-related Macular Degeneration
- Sponsor
- Bio-Thera Solutions (Industry)
- Enrolment
- 24 enrolled
- Conditions
- Age-related Macular Degeneration
- Interventions
- BAT5906 injection
- Ages
- adults, older adults
- Registry
- NCT04151212
Full record on ClinicalTrials.gov
From the registry
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
Primary outcomes
- Dose-limiting toxicity(DLT)
- Maximum tolerated dosed(MTD)
- Area under the curve(AUC0-t, AUC0-inf)
- Maximum serum drug concentration(Cmax)
History
Last registry update
Study completion
Primary completion
Registered
Started